SCIENTIFIC PROGRAMME

Wednesday, 9 October 2013

08.30-08.40 Opening ceremony 08.40-10.40 HBV infection in 2013 and future therapy
Chairmen: P. Marcellin, G. Papatheodoridis, F.Zoulim 1. Fabien Zoulim - Pathobiology of chronic HBV infections: clinical impact of the interplay between HBV and the intrahepatic innate responses 2. George Papatheodoridis - HCC risk in treated chronic hepatitis B patients 3. Emanuel Manesis - Significance of quantitative HBsAg in treatment of HBV infection 4. Laurentiu Micu - Management of HBV infection in special groups of patients 5. Patrick Marcellin - Treatment of HBV infection: present and future

10.40-12.00
1. 2. 3. 4.

HDV infection: where we are today and how we expect for tomorrow
Chairmen: C. Yurdaydin, Ch. Trepo

Cihan Yurdaydin - Treatment of HDV infection in 2013 Mithat Bozdayi - Epidemiology and treatment of HDV infection in Turkey Christian Trepo - TBA Zahari Krastev - Epidemiology and treatment of HDV infection in Bulgaria

12.00-13.30 Symposium - BMS I

13.30-14.00 Lunch break

14.00-16.00
1. 2. 3. 4.

HCV infection in 2013: some unresolved problems and future therapy (Part I)
Chairmen: A. Craxi, G. Dusheiko

Antonio Craxi - HCV infection and cardiovascular risk Christian Trepo - HCV therapy algorithm according to predictive biomarkers Geoffrey Dusheiko - New Therapies in hepatitis C: prospects limitations and unanswered questions Peter Ferenci - HCV-treatment in 2014 and beyond. When, whom to treat with what?

16.00-17.00 Symposium - BMS II

17.00-17.15 Coffee break

17.15-19.00
1. 2. 3. 4.

All HCV patients could be cured in the future? (Part II)

Chairmen: C. Hezode, T. Asselah

Christophe Hezode - Mechanism of HCV resistance to DAA Lawrence Serfaty - How to prevent and treat side effects of DAA Tarik Asselah - Future HCV Therapies Gabriela Oprisan - Viral mutations correlated with treatment response in chronic hepatitis C

Thursday, 10 October 2013

8.30 - 10.15

Is HCV - therapy cost effective and how can it made available for all
Chairmen: Achim Kautz,

1. Achim Kautz - The role of the Associations of Patients in Health Programmes 2. Adrian Streinu-Cercel - The importance of screening in HCV infection 3. Marinela Debu - TBA 4. Carmen Fierbinteanu - VHC and hepatocellular carcinoma: does antiviral treatment prevent this complication?

10.15 - 11.15 Symposium Roche 11.15 12.30

1. 2. 3. 4.

NASH (1) Chairmen: Vlad Ratziu, Dan Dumitrascu

Vlad Ratziu - Hepatocellular carcinoma in NASH patients Dan Dumitrascu - Gut flora and the fatty liver Raluca Pais - NAFLD and vascular risk Ana Carolina Cardoso TBA

12.30-13.30 Symposium MSD

13.30 - 14.00 Lunch break

14.00 16.00

NASH (2) Chairmen: Lawrence Serfaty, Carmen Fierbinteanu

1. Lawrence Serfaty - NAFLD and lifestyle 2. Adriana Popescu - TBA 3. Dan Olteanu - TBA 4. Mona Munteanu - What to treat first in chronic liver diseases: liver or heart? ... Responses of long-term prognosis with FibroMax biomarkers of chronic liver disease

16.00 - 16.30 Symposium Merz 16.30-17.00 Symposium Alfa Wassermann 17.00 19.00 Liver cirrhosis
Chairmen: L. De Carlis, A. Rampoldi 1. Dominique Thabut - Renal failure in cirrhotic patients 2. Carol Stanciu - Rare etiological forms of liver cirrhosis 3. Luciano De Carlis - TBA 4. Antonio Rampoldi - New data about TIPS 5. Ionel Copaci - Procoagulant status in liver cirrhosis

Friday, 11 October 2013

08.30-10.30 Complication of liver cirrhosis
Chairmen: Al.Oproiu, D.Olteanu 1. Alexandru Oproiu - Treatment of Esophageal variceal bleeding- strategies in 2013 2. Anca Trifan - Current therapies of portal encephalopathy 3. Camelia Achim - Renal involvement in liver cirrhosis: role of renal replacement therapies 4. Azra Husic-Selimovic - Coagulation disorder in liver cirrhosis

10.30 12.00

Liver carcinoma
Chairmen: M. Acalovschi, M.Voiculescu

1 Oliviu Pascu - Incidence and prevalence of HCC in Romania: risk factors or diagnostic problems? 2. Eugenia Mindrut - Epidemiology of HCC 3. Monica Acalovschi - Risk of hepatocarcinoma in VHB and VHC infections 4. Mihai Voiculescu - Multimodal treatment in hepatocellular carcinoma 5. Mugur Grasu - Ablation therapy for hepatocellular carcinoma

12.00-14.00 Symposium (TBA)

14.00 Closing ceremony